T's Pharma

T's Pharma is a Japanese specialty pharmaceutical company focused on the development and commercialization of drugs for rare and intractable diseases. The company primarily employs a drug repositioning strategy, identifying existing compounds that can be optimized for unmet medical needs in the Japanese market. Their lead product, TSP-02 (an intravenous formulation of valproic acid), is approved in Japan for the treatment of status epilepticus. T's Pharma maintains a lean organizational structure, focusing on clinical development and regulatory strategy while partnering for manufacturing and sales. The company was founded by industry veterans with extensive experience in the Japanese pharmaceutical sector, including former executives from Eisai. T's Pharma continues to expand its pipeline with a focus on neurology and other orphan indications.